Skip to main content

16.05.2024 | Original Article

Prediction of TNFRSF9 expression and molecular pathological features in thyroid cancer using machine learning to construct Pathomics models

verfasst von: Ying Liu, Junping Zhang, Shanshan Li, Wen Chen, Rongqian Wu, Zejin Hao, Jixiong Xu

Erschienen in: Endocrine

Einloggen, um Zugang zu erhalten

Abstract

Background

The TNFRSF9 molecule is pivotal in thyroid carcinoma (THCA) development. This study utilizes Pathomics techniques to predict TNFRSF9 expression in THCA tissue and explore its molecular mechanisms.

Methods

Transcriptome data, pathology images, and clinical information from the cancer genome atlas (TCGA) were analyzed. Image segmentation and feature extraction were performed using the OTSU’s algorithm and pyradiomics package. The dataset was split for training and validation. Features were selected using maximum relevance minimum redundancy recursive feature elimination (mRMR_RFE) and modeling conducted with the gradient boosting machine (GBM) algorithm. Model evaluation included receiver operating characteristic curve (ROC) analysis. The Pathomics model output a probabilistic pathomics score (PS) for gene expression prediction, with its prognostic value assessed in TNFRSF9 expression groups. Subsequent analysis involved gene set variation analysis (GSVA), immune gene expression, cell abundance, immunotherapy susceptibility, and gene mutation analysis.

Results

High TNFRSF9 expression correlated with worsened progression-free interval (PFI) and acted as an independent risk factor [hazard ratio (HR) = 2.178, 95% confidence interval (CI) 1.045–4.538, P = 0.038]. Nine pathohistological features were identified. The GBM Pathomics model demonstrated good prediction efficacy [area under the curve (AUC) 0.819 and 0.769] and clinical benefits. High PS was a PFI risk factor (HR = 2.156, 95% CI 1.047–4.440, P = 0.037). Patients with high PS potentially exhibited enriched pathways, increased TIGIT gene expression, Tregs infiltration (P < 0.0001), and higher rates of gene mutations (BRAF, TTN, TG).

Conclusions

The GBM Pathomics model constructed based on the pathohistological features of H&E-stained sections well predicted the expression level of TNFRSF9 molecules in THCA.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat F. Bray, J. Ferlay, I. Soerjomataram et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)CrossRefPubMed F. Bray, J. Ferlay, I. Soerjomataram et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018)CrossRefPubMed
2.
Zurück zum Zitat S. Vaccarella, S. Franceschi, F. Bray et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N. Engl. J. Med. 375(7), 614–617 (2016)CrossRefPubMed S. Vaccarella, S. Franceschi, F. Bray et al. Worldwide thyroid-cancer epidemic? The increasing impact of overdiagnosis. N. Engl. J. Med. 375(7), 614–617 (2016)CrossRefPubMed
3.
Zurück zum Zitat M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet. 388(10061), 2783–2795 (2016)CrossRefPubMed M.E. Cabanillas, D.G. McFadden, C. Durante, Thyroid cancer. Lancet. 388(10061), 2783–2795 (2016)CrossRefPubMed
4.
Zurück zum Zitat M. Pizzato, M. Li, J. Vignat et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10(4), 264–272 (2022)CrossRefPubMed M. Pizzato, M. Li, J. Vignat et al. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020. Lancet Diabetes Endocrinol. 10(4), 264–272 (2022)CrossRefPubMed
5.
6.
Zurück zum Zitat Y.K. Lee, N. Hong, S.H. Park et al. The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma. Sci. Rep. 9(1), 11435 (2019)CrossRefPubMedPubMedCentral Y.K. Lee, N. Hong, S.H. Park et al. The relationship of comorbidities to mortality and cause of death in patients with differentiated thyroid carcinoma. Sci. Rep. 9(1), 11435 (2019)CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat X. Han, J. Chen, J. Wang et al. TTN mutations predict a poor prognosis in patients with thyroid cancer. Biosci. Rep. 42(7), BSR20221168 (2022) X. Han, J. Chen, J. Wang et al. TTN mutations predict a poor prognosis in patients with thyroid cancer. Biosci. Rep. 42(7), BSR20221168 (2022)
8.
Zurück zum Zitat G. Vitale, G. Pellegrino, E. Desiderio et al. Radioiodine-refractory thyroid cancer: a complex challenge. Minerva Med. 112(6), 686–688 (2021)PubMed G. Vitale, G. Pellegrino, E. Desiderio et al. Radioiodine-refractory thyroid cancer: a complex challenge. Minerva Med. 112(6), 686–688 (2021)PubMed
9.
Zurück zum Zitat R. Pang, C. Qin, Development of a risk predictive model for evaluating immune infiltration status in invasive thyroid Carcinoma. Evid. Based Complement. Altern. Med. 2022, 5803077 (2022)CrossRef R. Pang, C. Qin, Development of a risk predictive model for evaluating immune infiltration status in invasive thyroid Carcinoma. Evid. Based Complement. Altern. Med. 2022, 5803077 (2022)CrossRef
10.
Zurück zum Zitat A. Fröhlich, S. Loick, E.G. Bawden et al. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine. 52, 102647 (2020)CrossRefPubMedPubMedCentral A. Fröhlich, S. Loick, E.G. Bawden et al. Comprehensive analysis of tumor necrosis factor receptor TNFRSF9 (4-1BB) DNA methylation with regard to molecular and clinicopathological features, immune infiltrates, and response prediction to immunotherapy in melanoma. EBioMedicine. 52, 102647 (2020)CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat C. Wang, G.H. Lin, A.J. McPherson et al. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol. Rev. 229(1), 192–215 (2009)CrossRefPubMed C. Wang, G.H. Lin, A.J. McPherson et al. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol. Rev. 229(1), 192–215 (2009)CrossRefPubMed
12.
Zurück zum Zitat S.W. Lee, A.T. Vella, B.S. Kwon et al. Enhanced CD4 T cell responsiveness in the absence of 4-1BB. J. Immunol. 174(11), 6803–6808 (2005)CrossRefPubMed S.W. Lee, A.T. Vella, B.S. Kwon et al. Enhanced CD4 T cell responsiveness in the absence of 4-1BB. J. Immunol. 174(11), 6803–6808 (2005)CrossRefPubMed
13.
Zurück zum Zitat W.T. Ho, W.L. Pang, S.M. Chong et al. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res. 73(2), 652–661 (2013)CrossRefPubMed W.T. Ho, W.L. Pang, S.M. Chong et al. Expression of CD137 on Hodgkin and Reed-Sternberg cells inhibits T-cell activation by eliminating CD137 ligand expression. Cancer Res. 73(2), 652–661 (2013)CrossRefPubMed
14.
Zurück zum Zitat J. Wu, Y. Wang, Y. Yang et al. TNFSF9 promotes metastasis of pancreatic cancer by regulating M2 polarization of macrophages through Src/FAK/p-Akt/IL-1β signaling. Int. Immunopharmacol. 102, 108429 (2022)CrossRefPubMed J. Wu, Y. Wang, Y. Yang et al. TNFSF9 promotes metastasis of pancreatic cancer by regulating M2 polarization of macrophages through Src/FAK/p-Akt/IL-1β signaling. Int. Immunopharmacol. 102, 108429 (2022)CrossRefPubMed
15.
Zurück zum Zitat V.G. Bhoj, L. Li, K. Parvathaneni et al. Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Mol. Ther. Oncolytics 20, 387–398 (2021)CrossRefPubMedPubMedCentral V.G. Bhoj, L. Li, K. Parvathaneni et al. Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. Mol. Ther. Oncolytics 20, 387–398 (2021)CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat B.C. Bertol, E.S. Bales, J.D. Calhoun et al. Lenvatinib plus Anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer. Thyroid. 32(2), 153–163 (2022)CrossRefPubMedPubMedCentral B.C. Bertol, E.S. Bales, J.D. Calhoun et al. Lenvatinib plus Anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer. Thyroid. 32(2), 153–163 (2022)CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat K. Liu, J. Hu, Classification of acute myeloid leukemia M1 and M2 subtypes using machine learning. Comput. Biol. Med. 147, 105741 (2022)CrossRefPubMed K. Liu, J. Hu, Classification of acute myeloid leukemia M1 and M2 subtypes using machine learning. Comput. Biol. Med. 147, 105741 (2022)CrossRefPubMed
18.
Zurück zum Zitat M. Nishio, M. Nishio, N. Jimbo et al. Homology-based image processing for automatic classification of histopathological images of lung tissue. Cancers. 13(6), 1192 (2021) M. Nishio, M. Nishio, N. Jimbo et al. Homology-based image processing for automatic classification of histopathological images of lung tissue. Cancers. 13(6), 1192 (2021)
19.
Zurück zum Zitat G.L. Banna, T. Olivier, F. Rundo et al. The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy. Front. Med. 6, 172 (2019)CrossRef G.L. Banna, T. Olivier, F. Rundo et al. The promise of digital biopsy for the prediction of tumor molecular features and clinical outcomes associated with immunotherapy. Front. Med. 6, 172 (2019)CrossRef
20.
Zurück zum Zitat J. Xie, L. Chen, Q. Tang et al. A necroptosis-related prognostic model of uveal melanoma was constructed by single-cell sequencing analysis and weighted co-expression network analysis based on public databases. Front. Immunol. 13, 847624 (2022)CrossRefPubMedPubMedCentral J. Xie, L. Chen, Q. Tang et al. A necroptosis-related prognostic model of uveal melanoma was constructed by single-cell sequencing analysis and weighted co-expression network analysis based on public databases. Front. Immunol. 13, 847624 (2022)CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat S. Zhang, S. Chen, Y. Wang et al. Association of a novel prognosis model with tumor mutation burden and tumor-infiltrating immune cells in thyroid carcinoma. Front. Genet. 12, 744304 (2021)CrossRefPubMedPubMedCentral S. Zhang, S. Chen, Y. Wang et al. Association of a novel prognosis model with tumor mutation burden and tumor-infiltrating immune cells in thyroid carcinoma. Front. Genet. 12, 744304 (2021)CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Y. Qin, D. Zhang, H. Zhang et al. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma. Cancer Cell Int. 22(1), 296 (2022)CrossRefPubMedPubMedCentral Y. Qin, D. Zhang, H. Zhang et al. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma. Cancer Cell Int. 22(1), 296 (2022)CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Y. Zhu, T. Yu, J. Huang et al. Development and validation of prognostic m6A-related lncRNA and mRNA model in thyroid cancer. Am. J. Cancer Res. 12(7), 3259–3279 (2022)PubMedPubMedCentral Y. Zhu, T. Yu, J. Huang et al. Development and validation of prognostic m6A-related lncRNA and mRNA model in thyroid cancer. Am. J. Cancer Res. 12(7), 3259–3279 (2022)PubMedPubMedCentral
24.
Zurück zum Zitat L. Chang, Y. Zhang, J. Zhu et al. An integrated nomogram combining deep learning, clinical characteristics and ultrasound features for predicting central lymph node metastasis in papillary thyroid cancer: a multicenter study. Front. Endocrinol. 14, 964074 (2023)CrossRef L. Chang, Y. Zhang, J. Zhu et al. An integrated nomogram combining deep learning, clinical characteristics and ultrasound features for predicting central lymph node metastasis in papillary thyroid cancer: a multicenter study. Front. Endocrinol. 14, 964074 (2023)CrossRef
25.
Zurück zum Zitat S. Peng, Y. Liu, W. Lv et al. Deep learning-based artificial intelligence model to assist thyroid nodule diagnosis and management: a multicentre diagnostic study. Lancet Digit Health 3(4), e250–e259 (2021)CrossRefPubMed S. Peng, Y. Liu, W. Lv et al. Deep learning-based artificial intelligence model to assist thyroid nodule diagnosis and management: a multicentre diagnostic study. Lancet Digit Health 3(4), e250–e259 (2021)CrossRefPubMed
26.
Zurück zum Zitat Q. Qi, X. Huang, Y. Zhang et al. Ultrasound image-based deep learning to assist in diagnosing gross extrathyroidal extension thyroid cancer: a retrospective multicenter study. EClinicalMedicine 58, 101905 (2023)CrossRefPubMedPubMedCentral Q. Qi, X. Huang, Y. Zhang et al. Ultrasound image-based deep learning to assist in diagnosing gross extrathyroidal extension thyroid cancer: a retrospective multicenter study. EClinicalMedicine 58, 101905 (2023)CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat F. Li, D. Pan, Y. He et al. Using ultrasound features and radiomics analysis to predict lymph node metastasis in patients with thyroid cancer. BMC Surg. 20(1), 315 (2020)CrossRefPubMedPubMedCentral F. Li, D. Pan, Y. He et al. Using ultrasound features and radiomics analysis to predict lymph node metastasis in patients with thyroid cancer. BMC Surg. 20(1), 315 (2020)CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat W. He, Y. Sun, J. Ge et al. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma. Front. Endocrinol. 14, 1076640 (2023)CrossRef W. He, Y. Sun, J. Ge et al. STRA6 regulates tumor immune microenvironment and is a prognostic marker in BRAF-mutant papillary thyroid carcinoma. Front. Endocrinol. 14, 1076640 (2023)CrossRef
29.
Zurück zum Zitat X. Zhu, C. Chen, Q. Guo et al. Deep learning-based recognition of different thyroid cancer categories using whole frozen-slide images. Front. Bioeng. Biotechnol. 10, 857377 (2022)CrossRefPubMedPubMedCentral X. Zhu, C. Chen, Q. Guo et al. Deep learning-based recognition of different thyroid cancer categories using whole frozen-slide images. Front. Bioeng. Biotechnol. 10, 857377 (2022)CrossRefPubMedPubMedCentral
30.
31.
Zurück zum Zitat K. Ikegami, S. Refetoff, E. Van Cauter et al. Interconnection between circadian clocks and thyroid function. Nat. Rev. Endocrinol. 15(10), 590–600 (2019)CrossRefPubMedPubMedCentral K. Ikegami, S. Refetoff, E. Van Cauter et al. Interconnection between circadian clocks and thyroid function. Nat. Rev. Endocrinol. 15(10), 590–600 (2019)CrossRefPubMedPubMedCentral
32.
33.
Zurück zum Zitat D. Zhang, R.R. Jones, P. James et al. Associations between artificial light at night and risk for thyroid cancer: a large US cohort study. Cancer. 127(9), 1448–1458 (2021)CrossRefPubMed D. Zhang, R.R. Jones, P. James et al. Associations between artificial light at night and risk for thyroid cancer: a large US cohort study. Cancer. 127(9), 1448–1458 (2021)CrossRefPubMed
34.
Zurück zum Zitat F. Di Cara, S. Savary, W.J. Kovacs et al. The peroxisome: an up-and-coming organelle in immunometabolism. Trends Cell Biol. 33(1), 70–86 (2023)CrossRefPubMed F. Di Cara, S. Savary, W.J. Kovacs et al. The peroxisome: an up-and-coming organelle in immunometabolism. Trends Cell Biol. 33(1), 70–86 (2023)CrossRefPubMed
35.
Zurück zum Zitat E. Semikasev, B. Ahlemeyer, T. Acker et al. Rise and fall of peroxisomes during Alzheimer´s disease: a pilot study in human brains. Acta Neuropathol. Commun. 11(1), 80 (2023)CrossRefPubMedPubMedCentral E. Semikasev, B. Ahlemeyer, T. Acker et al. Rise and fall of peroxisomes during Alzheimer´s disease: a pilot study in human brains. Acta Neuropathol. Commun. 11(1), 80 (2023)CrossRefPubMedPubMedCentral
37.
Zurück zum Zitat A. Rotte, S. Sahasranaman, N. Budha, Targeting TIGIT for immunotherapy of cancer: update on clinical development. Biomedicines. 9(9), 1277 (2021) A. Rotte, S. Sahasranaman, N. Budha, Targeting TIGIT for immunotherapy of cancer: update on clinical development. Biomedicines. 9(9), 1277 (2021)
38.
Zurück zum Zitat S. Kurtulus, K. Sakuishi, S.F. Ngiow et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 125(11), 4053–4062 (2015)CrossRefPubMedPubMedCentral S. Kurtulus, K. Sakuishi, S.F. Ngiow et al. TIGIT predominantly regulates the immune response via regulatory T cells. J Clin Invest 125(11), 4053–4062 (2015)CrossRefPubMedPubMedCentral
39.
Zurück zum Zitat J. Niu, C. Maurice-Dror, D.H. Lee et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(☆). Ann. Oncol. 33(2), 169–180 (2022)CrossRefPubMed J. Niu, C. Maurice-Dror, D.H. Lee et al. First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer(☆). Ann. Oncol. 33(2), 169–180 (2022)CrossRefPubMed
Metadaten
Titel
Prediction of TNFRSF9 expression and molecular pathological features in thyroid cancer using machine learning to construct Pathomics models
verfasst von
Ying Liu
Junping Zhang
Shanshan Li
Wen Chen
Rongqian Wu
Zejin Hao
Jixiong Xu
Publikationsdatum
16.05.2024
Verlag
Springer US
Erschienen in
Endocrine
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-024-03862-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.